Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO, BIOB · Entity 2247 | EVP, Chief Operating Officer | September 13, 2017 | September 14, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date September 13, 2017 · Filed September 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 66,473.3235 |
Ending reported balance
After 2017-09-13 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2017-09-13 · Exercise / conversion · Acquired 650 · Balance 66,067.3235 Row 2 · 2017-09-13 · Tax withholding · Disposed 491 · Balance 65,576.3235 Row 3 · 2017-09-13 · Exercise / conversion · Acquired 640 · Balance 66,216.3235 Row 4 · 2017-09-13 · Tax withholding · Disposed 497 · Balance 65,719.3235 Row 5 · 2017-09-13 · Exercise / conversion · Acquired 1,200 · Balance 66,919.3235 Row 6 · 2017-09-13 · Tax withholding · Disposed 938 · Balance 65,981.3235 Row 7 · 2017-09-13 · Exercise / conversion · Acquired 1,600 · Balance 67,581.3235 Row 8 · 2017-09-13 · Tax withholding · Disposed 1,320 · Balance 66,261.3235 Row 9 · 2017-09-13 · Exercise / conversion · Acquired 1,600 · Balance 67,861.3235 Row 10 · 2017-09-13 · Tax withholding · Disposed 1,388 · Balance 66,473.3235 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.32 · Expires 2022-09-12 | Direct | 0 |
Reported balance
After 2017-09-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-09-13 · Exercise / conversion · Disposed 650 · Balance 0 F1: The option vests in five equal annual installments beginning September 12, 2013. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $117.00 · Expires 2023-09-11 | Direct | 640 |
Reported balance
After 2017-09-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-09-13 · Exercise / conversion · Disposed 640 · Balance 640 F2: The option vests in five equal annual installments beginning September 11, 2014. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $119.54 · Expires 2024-09-10 | Direct | 2,400 |
Reported balance
After 2017-09-13 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-09-13 · Exercise / conversion · Disposed 1,200 · Balance 2,400 F3: The option vests in five equal annual installments beginning September 10, 2015. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.56 · Expires 2025-09-11 | Direct | 4,800 |
Reported balance
After 2017-09-13 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2017-09-13 · Exercise / conversion · Disposed 1,600 · Balance 4,800 F4: The option vests in five equal annual installments beginning September 11, 2016. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $159.32 · Expires 2026-09-07 | Direct | 6,400 |
Reported balance
After 2017-09-13 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2017-09-13 · Exercise / conversion · Disposed 1,600 · Balance 6,400 F5: The option vests in five equal annual installments beginning September 7, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in five equal annual installments beginning September 12, 2013.
F2: The option vests in five equal annual installments beginning September 11, 2014.
F3: The option vests in five equal annual installments beginning September 10, 2015.
F4: The option vests in five equal annual installments beginning September 11, 2016.
F5: The option vests in five equal annual installments beginning September 7, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2017 Filed May 11, 2017 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 2,462 | $223.00 | $549,026.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 4 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,237.1596 Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 3,500 | $84.57 | $295,995.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 3 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,699.1596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 2,271 | $223.00 | $506,433.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 2 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,199.1596 Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 3,500 | $74.27 | $259,945.00 |
DisclosureSEC source: 0001652252-17-000031 · edgar.xml · nonDerivative · entry 1 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,470.1596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 47.7598 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2017. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 00:21 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $75.32 | $0.00 |
DisclosureSEC source: 0001652252-17-000004 · edgar.xml · derivative · entry 3 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2017-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in five equal annual installments beginning on August 1, 2008. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 00:21 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 3,500 | $196.34 | $687,188.60 |
DisclosureSEC source: 0001652252-17-000004 · edgar.xml · nonDerivative · entry 2 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,922.3998 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.306 to $196.415 inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 00:21 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 3,500 | $75.32 | $263,620.00 |
DisclosureSEC source: 0001652252-17-000004 · edgar.xml · nonDerivative · entry 1 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,422.3998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4.6707 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 12/31/2016. Read SEC document |
| November 04, 2016 Filed Nov 8, 2016 18:34 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000128 · edgar.xml · derivative · entry 3 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning November 4, 2012. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning November 4, 2012. Read SEC document |
| November 04, 2016 Filed Nov 8, 2016 18:34 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 126 | $164.74 | $20,757.24 |
DisclosureSEC source: 0001652252-16-000128 · edgar.xml · nonDerivative · entry 2 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,917.7287 Read SEC document |
| November 04, 2016 Filed Nov 8, 2016 18:34 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000128 · edgar.xml · nonDerivative · entry 1 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,043.7287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 59.3088 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 9/30/16. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · derivative · entry 10 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Bio-Rad A Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 12, 2013. F6 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 12, 2013. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 157 | $159.32 | $25,013.24 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · nonDerivative · entry 6 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,744.4199 Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · nonDerivative · entry 5 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,901.4199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 11, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · derivative · entry 9 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Underlying: Bio-Rad A Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. F5 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 11, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · derivative · entry 8 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2014. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2014. Read SEC document |
| September 11, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 915 | $157.71 | $144,304.65 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · nonDerivative · entry 4 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,601.4199 Read SEC document |
| September 11, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · nonDerivative · entry 3 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,516.4199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · derivative · entry 7 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Bio-Rad A Common Stock · 1,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 451 | $157.71 | $71,127.21 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · nonDerivative · entry 2 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,616.4199 Read SEC document |
| September 10, 2016 Filed Sep 13, 2016 22:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000108 · edgar.xml · nonDerivative · entry 1 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,067.4199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:51 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-16-000079 · edgar.xml · derivative · entry 3 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Bio-Rad A Common Stock · 8,000 shares Expires 2026-09-07 F4 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:51 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 8,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000079 · edgar.xml · derivative · entry 2 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Bio-Rad A Common Stock · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.